3 news items
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
ELDN
3 Jun 24
of which are side effects often associated with standard of care immunosuppression therapy. There have been no cases of graft loss or death
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
ELDN
7 May 24
or death.
Eledon is currently conducting a Phase 1b trial, the Phase 2 BESTOW trial, and a Long-Term Safety and Efficacy extension study
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
ELDN
7 May 24
and fatigue, viral infection, and rejection, respectively. There have been no cases of graft loss or death. The company plans to present this data
- Prev
- 1
- Next